Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  International Journal of Biochemistry and Cell Biology

• Publication date

  2018-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.biocel.2017.12.010PMID 29247711
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.

  2017cited by this paper
• Cancer statistics, 2016

  2016cited by this paper
• Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma

  2016cited by this paper
• Inhibition of autophagy sensitizes MDR-phenotype ovarian cancer SKVCR cells to chemotherapy.

  2016cited by this paper
• Downregulation of ATG14 by EGR1-MIR152 sensitizes ovarian cancer cells to cisplatin-induced apoptosis by inhibiting cyto-protective autophagy

  2015cited by this paper
• Autophagy in cancer

  2015cited by this paper
• Treatment options in recurrent ovarian cancer: latest evidence and clinical potential

  2014cited by this paper
• Induction of autophagy contributes to cisplatin resistance in human ovarian cancer cells

  2014cited by this paper
• Hexokinase-II positively regulates glucose starvation-induced autophagy through TORC1 inhibition.

  2014cited by this paper
• Expression of hexokinase 2 in epithelial ovarian tumors and its clinical significance in serous ovarian cancer.

  2014cited by this paper
• Association of overexpression of hexokinase II with chemoresistance in epithelial ovarian cancer

  2014cited by this paper
• Role of Autophagy in Cisplatin Resistance in Ovarian Cancer Cells*

  2014cited by this paper
• MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells.

  2013cited by this paper
• Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment

  2013cited by this paper
• 2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth.

  2013cited by this paper
• Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy

  2013cited by this paper
• The autophagy protein LC3A correlates with hypoxia and is a prognostic marker of patient survival in clear cell ovarian cancer

  2012cited by this paper
• Combined RNA Interference of Hexokinase II and 131I-Sodium Iodide Symporter Gene Therapy for Anaplastic Thyroid Carcinoma

  2011cited by this paper
• Frequent genetic abnormalities of the PI3K/AKT pathway in primary ovarian cancer predict patient outcome

  2011cited by this paper
• Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.

  2011cited by this paper
• Autophagy: Renovation of Cells and Tissues

  2011cited by this paper
• ERK and cell death: Mechanisms of ERK‐induced cell death – apoptosis, autophagy and senescence

  2010cited by this paper
• The mTOR pathway: a new target in cancer therapy.

  2010cited by this paper
• Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.

  2009cited by this paper
• Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate.

  2009cited by this paper
• Voltage-dependent Anion Channel 1-based Peptides Interact with Hexokinase to Prevent Its Anti-apoptotic Activity*

  2009cited by this paper
• Voltage dependent anion channels (VDACs): a brief introduction with a focus on the outer mitochondrial compartment’s roles together with hexokinase-2 in the “Warburg effect” in cancer

  2008cited by this paper
• Inhibition of ERK attenuates autophagy and potentiates tumour necrosis factor-α-induced cell death in MCF-7 cells

  2008cited by this paper
• Cancer cell metabolism: Warburg and beyond.

  2008cited by this paper
• The mode of cisplatin-induced cell death in CYP2E1-overexpressing HepG2 cells: modulation by ERK, ROS, glutathione, and thioredoxin.

  2007cited by this paper
• In self-defence: hexokinase promotes voltage-dependent anion channel closure and prevents mitochondria-mediated apoptotic cell death.

  2004cited by this paper
• 2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo

  2004cited by this paper
• Role of ERK activation in cisplatin-induced apoptosis in A172 human glioma cells.

  2004cited by this paper
• Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function

  2003cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.

  2001cited by this paper
• Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study.

  2001cited by this paper
• Erk1/2-dependent Phosphorylation of Gα-interacting Protein Stimulates Its GTPase Accelerating Activity and Autophagy in Human Colon Cancer Cells*

  2000cited by this paper
• Requirement for ERK Activation in Cisplatin-induced Apoptosis*

  2000cited by this paper
• Cisplatin‐induced response of c‐jun N‐terminal kinase 1 and extracellular signal‐regulated protein kinases 1 and 2 in a series of cisplatin‐resistant ovarian carcinoma cell lines

  2000cited by this paper
• Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin.

  1999cited by this paper
• Inhibition of Extracellular Signal-regulated Protein Kinase or c-Jun N-terminal Protein Kinase Cascade, Differentially Activated by Cisplatin, Sensitizes Human Ovarian Cancer Cell Line*

  1999cited by this paper
• Gamma-glutamyl cysteine synthetase up-regulates glutathione and multidrug resistance-associated protein in patients with chemoresistant epithelial ovarian cancer.

  1998cited by this paper
• Revertant and potentiating activity of lonidamine in patients with ovarian cancer previously treated with platinum.

  1997cited by this paper
• Use of lonidamine to potentiate the effect of cisplatin and carboplatin on platinum resistant human ovarian cancer cells.

  1997cited by this paper
• Aberrant Glycolytic Metabolism of Cancer Cells: A Remarkable Coordination of Genetic, Transcriptional, Post-translational, and Mutational Events That Lead to a Critical Role for Type II Hexokinase

  1997cited by this paper
• Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues.

  1987cited by this paper

• Novel Pt@BSA nanoparticles improve radiotherapeutic outcomes in breast cancer.

  2026cites this paper
• Metabolic reprogramming-driven resistance to multi-kinase inhibitors in hepatocellular carcinoma: molecular mechanisms and therapeutic opportunities

  2026cites this paper
• The moonlighting functions of glycolytic enzymes in tumorigenesis

  2026cites this paper
• The role of circadian disruption, sleep dysregulation, lifestyle factors, and metabolic reprogramming in the pathogenesis and progression of ovarian cancer

  2026cites this paper
• Therapeutic targeting of post-translational modifications in ovarian cancer: mechanisms and clinical applications

  2025cites this paper
• Autophagy induced by metabolic processes leads to solid tumor cell metastatic dormancy and recurrence

  2025cites this paper
• Novel factors of cisplatin resistance in epithelial ovarian tumours.

  2025cites this paper
• Transketolase attenuates the chemotherapy sensitivity of glioma cells by modulating R-loop formation.

  2025cites this paper
• Targeting ncRNAs to overcome metabolic reprogramming-mediated drug resistance in cancer (Review)

  2025cites this paper
• The emerging role of glycolysis and immune evasion in ovarian cancer

  2025cites this paper
• Therapeutic management of PI3Kα inhibitor-induced hyperglycemia with a novel glucokinase activator: Advancing the Frontier of PI3Kα inhibitor therapy

  2025cites this paper
• The role and therapeutic potential of glucose metabolism in multidrug resistance of cancer

  2025cites this paper
• Cold atmospheric plasma-activated liquid inhibits peritoneal metastasis in drug-resistant ovarian cancer by targeting the epithelial-mesenchymal transition

  2025cites this paper
• Overcoming cisplatin resistance in ovarian cancer: A novel approach via mitochondrial targeting peptide Pal-pHK-pKV.

  2024cites this paper
• Targeting mitochondria: a novel approach for treating platinum-resistant ovarian cancer

  2024cites this paper
• Epigenetics as a strategic intervention for early diagnosis and combatting glycolyis-induced chemoresistance in gynecologic cancers.

  2024cites this paper
• RON receptor tyrosine kinase regulates glycolysis through MAPK/CREB signaling to affect ferroptosis and chemotherapy sensitivity of thyroid cancer cells

  2024cites this paper
• Cisplatin Resistance and Metabolism: Simplification of Complexity

  2024cites this paper
• Diagnosis of Cutaneous Acute Graft‑Versus‑Host Disease Through Circulating Plasma miR‐638, miR‐6511b‐5p, miR‐3613‐5p, miR‐455‐3p, miR‐5787, and miR‐548a‐3p as Prospective Noninvasive Biomarkers Following Allogeneic Hematopoietic Stem Cell Transplantation

  2024cites this paper
• The regulatory roles and clinical significance of glycolysis in tumor

  2024cites this paper
• The PI3K/Akt Pathway and Glucose Metabolism: A Dangerous Liaison in Cancer

  2024cites this paper
• CCT6A facilitates lung adenocarcinoma progression and glycolysis via STAT1/HK2 axis

  2024cites this paper
• Abnormal changes in metabolites caused by m6A methylation modification: The leading factors that induce the formation of immunosuppressive tumor microenvironment and their promising potential for clinical application

  2024cites this paper
• Cisplatin-Resistant Urothelial Bladder Cancer Cells Undergo Metabolic Reprogramming beyond the Warburg Effect

  2024cites this paper
• Exploiting Co(III)-Cyclopentadienyl Complexes To Develop Anticancer Agents

  2024cites this paper
• Autophagy-driven regulation of cisplatin response in human cancers: Exploring molecular and cell death dynamics.

  2024cites this paper
• Glycolytic enzymes in non-glycolytic web: functional analysis of the key players

  2024cites this paper
• Inhibition of lncRNA RPPH1 activity decreases tumor proliferation and metastasis through down-regulation of inflammation-related oncogenes.

  2023cites this paper
• Hexokinase inhibitor 2-deoxyglucose coordinates citrullination of vimentin and apoptosis of fibroblast-like synoviocytes by inhibiting HK2 /mTORC1-induced autophagy.

  2023cites this paper
• Mitochondrion: Main organelle in orchestrating cancer escape from chemotherapy

  2023cites this paper
• Ferroptosis, Metabolic Rewiring, and Endometrial Cancer

  2023cites this paper
• HK2 contributes to the proliferation, migration, and invasion of diffuse large B-cell lymphoma cells by enhancing the ERK1/2 signaling pathway

  2023cites this paper
• Deciphering the Mysterious Relationship between the Cross-Pathogenetic Mechanisms of Neurodegenerative and Oncological Diseases

  2023cites this paper
• Gastrodin overcomes chemoresistance via inhibiting Skp2-mediated glycolysis

  2023cites this paper
• Metabolic reprogramming of three major nutrients in platinum-resistant ovarian cancer

  2023cites this paper
• Autophagy and Glycometabolic Reprograming in the Malignant Progression of Lung Cancer: A Review

  2023cites this paper
• Isoalantolactone Suppresses Glycolysis and Resensitizes Cisplatin-Based Chemotherapy in Cisplatin-Resistant Ovarian Cancer Cells

  2023cites this paper
• Molecular mechanisms of cisplatin resistance in ovarian cancer

  2023cites this paper
• Oncogenic alterations of metabolism associated with resistance to chemotherapy.

  2023cites this paper
• The sequestosome 1 protein: therapeutic vulnerabilities in ovarian cancer

  2023cites this paper
• Inhibition of IDH3α Enhanced the Efficacy of Chemoimmunotherapy by Regulating Acidic Tumor Microenvironments

  2023cites this paper
• Glucose Metabolism Reprogramming in Bladder Cancer: Hexokinase 2 (HK2) as Prognostic Biomarker and Target for Bladder Cancer Therapy

  2023cites this paper
• Long noncoding RNAs: glycolysis regulators in gynaecologic cancers

  2023cites this paper
• Increased response to TPF chemotherapy promotes immune escape in hypopharyngeal squamous cell carcinoma

  2023cites this paper
• Hexokinases in cancer and other pathologies

  2023cites this paper
• Tumor Cell Glycolysis—At the Crossroad of Epithelial–Mesenchymal Transition and Autophagy

  2022cites this paper
• Placenta autophagy is closely associated with preeclampsia

  2022cites this paper
• Early Reduction of Glucose Consumption Is a Biomarker of Kinase Inhibitor Efficacy Which Can Be Reversed with GLUT1 Overexpression in Lung Cancer Cells

  2022cites this paper
• Photochemical Targeting of Mitochondria to Overcome Chemoresistance in Ovarian Cancer †

  2022cites this paper
• The histone deacetylase SIRT6 promotes glycolysis through the HIF-1α/HK2 signaling axis and induces erlotinib resistance in non-small cell lung cancer

  2022cites this paper
• Cellular landscaping of cisplatin resistance in cervical cancer.

  2022cites this paper
• Hexokinase 1b is a novel target for Non–small-cell lung cancer

  2022cites this paper
• Tumor metabolic reprogramming in lung cancer progression

  2022cites this paper
• Recent advances in understanding the metabolic plasticity of ovarian cancer: A systematic review

  2022cites this paper
• PGC-1α participates in tumor chemoresistance by regulating glucose metabolism and mitochondrial function

  2022cites this paper
• Non-apoptotic cell death in ovarian cancer: Treatment, resistance and prognosis.

  2022cites this paper
• Molecular characterization of glyceraldehyde-3-phosphate dehydrogenase from Eimeria tenella

  2022cites this paper
• Circular RNA pyridoxal kinase (circPDXK) involves in the progression of ovarian cancer and glycolysis via regulating miR-654-3p and hexokinase II

  2022influential citation
• Warburg and pasteur phenotypes modulate cancer behavior and therapy

  2021cites this paper
• Epigenetic control of autophagy in women’s tumors: role of non-coding RNAs

  2021cites this paper
• Metabolic Strategies for Inhibiting Cancer Development.

  2021cites this paper
• Autophagy signals orchestrate chemoresistance of gynecological cancers.

  2021cites this paper
• Nanocarrier‐delivered small interfering RNA for chemoresistant ovarian cancer therapy

  2021cites this paper
• PGC1α Promotes Cisplatin Resistance in Ovarian Cancer by Regulating the HSP70/HK2/VDAC1 Signaling Pathway

  2021cites this paper
• Cell Metabolism and DNA Repair Pathways: Implications for Cancer Therapy

  2021cites this paper
• SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis

  2021cites this paper
• Shifting the Gears of Metabolic Plasticity to Drive Cell State Transitions in Cancer

  2021cites this paper
• Metabolic Classification and Intervention Opportunities for Tumor Energy Dysfunction

  2021cites this paper
• Hexokinase 2 in Cancer: A Prima Donna Playing Multiple Characters

  2021cites this paper
• Pathogenesis and therapeutic strategy in platinum resistance lung cancer.

  2021cites this paper
• The Role of Tumour Metabolism in Cisplatin Resistance

  2021cites this paper
• Long non-coding RNA DLEU2 drives EMT and glycolysis in endometrial cancer through HK2 by competitively binding with miR-455 and by modulating the EZH2/miR-181a pathway

  2021cites this paper
• Extracellular Vesicle Transmission of Chemoresistance to Ovarian Cancer Cells Is Associated with Hypoxia-Induced Expression of Glycolytic Pathway Proteins, and Prediction of Epithelial Ovarian Cancer Disease Recurrence

  2021cites this paper
• Autophagy up-regulated by MEK/ERK promotes the repair of DNA damage caused by aflatoxin B1

  2021cites this paper
• The Mechanism of Warburg Effect-Induced Chemoresistance in Cancer

  2021cites this paper
• Recent progress of autophagy signaling in tumor microenvironment and its targeting for possible cancer therapeutics.

  2021cites this paper
• Overcoming drug resistance in ovarian cancer: Chemo-sensitizing agents, targeted therapies

  2021cites this paper
• Drug resistance in gynecologic cancers: Emphasis on noncoding RNAs and drug efflux mechanisms

  2021cites this paper
• Histone H2AX promotes metastatic progression by preserving glycolysis via hexokinase-2

  2021cites this paper
• The Key Role of the WNT/β-Catenin Pathway in Metabolic Reprogramming in Cancers under Normoxic Conditions

  2021cites this paper
• Deciphering the impact of lipid metabolism in breast cancer cells

  2021cites this paper
• Regulation of Autophagy by Glycolysis in Cancer

  2020cites this paper
• Bioinformatics Analysis of TIMP1, HK2 and IGFBP7 as Potential Biomarkers and Therapeutic Targets of Paclitaxel Resistance in Breast Cancer

  2020cites this paper
• Autophagy Takes Center Stage as a Possible Cancer Hallmark

  2020cites this paper
• Hexokinase inhibition using D-Mannoheptulose enhances oncolytic newcastle disease virus-mediated killing of breast cancer cells

  2020cites this paper
• Therapy Resistance in Cancers: Phenotypic, Metabolic, Epigenetic and Tumour Microenvironmental Perspectives.

  2020cites this paper
• MiR-3662 suppresses cell growth, invasion and glucose metabolism by targeting HK2 in hepatocellular carcinoma cells.

  2020cites this paper
• Shenmai Injection Supresses Glycolysis and Enhances Cisplatin Cytotoxicity in Cisplatin-Resistant A549/DDP Cells via the AKT-mTOR-c-Myc Signaling Pathway

  2020cites this paper
• LncRNA-DANCR Interferes With miR-125b-5p/HK2 Axis to Desensitize Colon Cancer Cells to Cisplatin vis Activating Anaerobic Glycolysis

  2020cites this paper
• Gomisin J inhibits the glioma progression by inducing apoptosis and reducing HKII-regulated glycolysis.

  2020cites this paper
• Mitochondria Participate in Chemoresistance to Cisplatin in Human Ovarian Cancer Cells

  2020cites this paper
• Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis

  2020cites this paper
• Reactive Oxygen Species, Metabolic Plasticity, and Drug Resistance in Cancer

  2020cites this paper
• Modulation of non-coding RNAs by resveratrol in ovarian cancer cells: In silico analysis and literature review of the anti-cancer pathways involved

  2020cites this paper
• Insight into the role of p62 in the cisplatin resistant mechanisms of ovarian cancer

  2020cites this paper
• MS-275 combined with cisplatin exerts synergistic antitumor effects in human esophageal squamous cell carcinoma cells.

  2020cites this paper
• Unlocking the potential of HK2 in cancer metabolism and therapeutics.

  2020cites this paper
• Links between cancer metabolism and cisplatin resistance.

  2020cites this paper
• Regulatory Role of Hexokinase 2 in Modulating Head and Neck Tumorigenesis

  2020cites this paper
• Phototherapy alters the oncogenic metabolic activity of the breast cancer cells.

  2020cites this paper